Sign In
Buy STE
STERIS Earnings Calls
| Release date | Nov 05, 2025 |
| EPS estimate | $2.38 |
| EPS actual | $2.47 |
| EPS Surprise | 3.78% |
| Revenue estimate | 1.486B |
| Revenue actual | 1.46B |
| Revenue Surprise | -1.73% |
| Release date | Aug 06, 2025 |
| EPS estimate | $2.26 |
| EPS actual | $2.34 |
| EPS Surprise | 3.54% |
| Revenue estimate | 1.363B |
| Revenue actual | 1.391B |
| Revenue Surprise | 2.09% |
| Release date | May 14, 2025 |
| EPS estimate | $2.60 |
| EPS actual | $2.74 |
| EPS Surprise | 5.38% |
| Revenue estimate | 1.469B |
| Revenue actual | 1.481B |
| Revenue Surprise | 0.783% |
| Release date | Feb 05, 2025 |
| EPS estimate | $2.33 |
| EPS actual | $2.32 |
| EPS Surprise | -0.429% |
| Revenue estimate | 1.382B |
| Revenue actual | 1.371B |
| Revenue Surprise | -0.82% |
Last 4 Quarters for STERIS
Below you can see how STE performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Feb 05, 2025 |
| Price on release | $220.83 |
| EPS estimate | $2.33 |
| EPS actual | $2.32 |
| EPS surprise | -0.429% |
| Date | Price |
|---|---|
| Jan 30, 2025 | $221.70 |
| Jan 31, 2025 | $220.65 |
| Feb 03, 2025 | $218.34 |
| Feb 04, 2025 | $219.40 |
| Feb 05, 2025 | $220.83 |
| Feb 06, 2025 | $225.44 |
| Feb 07, 2025 | $223.23 |
| Feb 10, 2025 | $224.31 |
| Feb 11, 2025 | $223.36 |
| 4 days before | -0.392% |
| 4 days after | 1.15% |
| On release day | 2.09% |
| Change in period | 0.749% |
| Release date | May 14, 2025 |
| Price on release | $227.50 |
| EPS estimate | $2.60 |
| EPS actual | $2.74 |
| EPS surprise | 5.38% |
| Date | Price |
|---|---|
| May 08, 2025 | $225.86 |
| May 09, 2025 | $226.43 |
| May 12, 2025 | $233.10 |
| May 13, 2025 | $231.15 |
| May 14, 2025 | $227.50 |
| May 15, 2025 | $246.88 |
| May 16, 2025 | $251.59 |
| May 19, 2025 | $252.55 |
| May 20, 2025 | $250.47 |
| 4 days before | 0.726% |
| 4 days after | 10.10% |
| On release day | 8.52% |
| Change in period | 10.90% |
| Release date | Aug 06, 2025 |
| Price on release | $221.21 |
| EPS estimate | $2.26 |
| EPS actual | $2.34 |
| EPS surprise | 3.54% |
| Date | Price |
|---|---|
| Jul 31, 2025 | $226.49 |
| Aug 01, 2025 | $226.87 |
| Aug 04, 2025 | $228.43 |
| Aug 05, 2025 | $223.87 |
| Aug 06, 2025 | $221.21 |
| Aug 07, 2025 | $236.24 |
| Aug 08, 2025 | $242.85 |
| Aug 11, 2025 | $241.62 |
| Aug 12, 2025 | $243.76 |
| 4 days before | -2.33% |
| 4 days after | 10.19% |
| On release day | 6.79% |
| Change in period | 7.63% |
| Release date | Nov 05, 2025 |
| Price on release | $243.18 |
| EPS estimate | $2.38 |
| EPS actual | $2.47 |
| EPS surprise | 3.78% |
| Date | Price |
|---|---|
| Oct 30, 2025 | $236.19 |
| Oct 31, 2025 | $235.70 |
| Nov 03, 2025 | $237.32 |
| Nov 04, 2025 | $241.85 |
| Nov 05, 2025 | $243.18 |
| Nov 06, 2025 | $260.06 |
| Nov 07, 2025 | $263.77 |
| Nov 10, 2025 | $264.02 |
| Nov 11, 2025 | $266.70 |
| 4 days before | 2.96% |
| 4 days after | 9.67% |
| On release day | 6.94% |
| Change in period | 12.92% |
STERIS Earnings Call Transcript Summary of Q3 2025
STERIS reported a solid Q3: total and constant-currency organic revenue grew ~6% driven by volume and ~240 bps of price. Gross margin improved to 44.6% and adjusted EPS from continuing operations was $2.32 (up 11% YoY). Key financials: capital expenditures for first 9 months $299M, D&A $354M, free cash flow YTD $588M and management expects full-year FCF of ~ $700M, total debt $2.2B and gross leverage ~1.5x. Management tightened FY25 guidance with as‑reported revenue and constant‑currency organic growth both targeted at ~6% and adjusted EPS narrowed to $9.05–$9.15 (including an estimated ~$0.10 headwind from negative currency).
Segment highlights: Healthcare constant‑currency organic revenue +7% with strong recurring consumables and services (outperformance driven by U.S. procedure volumes, pricing and share gains); Healthcare capital equipment revenue declined ~5% due to shipment timing despite >10% order growth and a $435M backlog. AST constant‑currency organic revenue +10%, led by services and stronger-than-expected bioprocessing demand; Life Sciences declined ~1% CC driven by weaker capital equipment but margins improved materially (benefitting from favorable mix and CECS divestiture).
Expenses and risks: EBIT margin modestly down (10 bps) with litigation related to ethylene oxide (Isometix) and higher employee healthcare utilization adding >$10M incremental expense YoY in Q3; management expects modest additional EO legal expense (~$5M) in Q4. The first EO trial ended in a mistrial and is set for retrial in May; management says they will continue to vigorously defend the business. Other headwinds include negative currency and elevated labor/energy costs in some businesses. Management reiterated no material cancellations in backlog and emphasized productivity gains in Healthcare.
